偶氮二甲氧基异庚腈 | 15545-97-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 偶氮二甲氧基异庚腈
• 中文别名: 2,2'-偶氮雙(4-甲氧-2,4-二甲基戊腈)
• 英文名称: 2,2’-azobis(4-methoxy-2,4-dimethyl)valeronitrile
• 英文别名: 2,2’-azobis(4-methoxy-2,4-dimethylvaleronitrile)；2,2′-azobis(4-methoxy-2,4-dimethylvaleronitrile)；2,2′-azobis(4-methoxy-2,4-dimethylvaleronitril)；2 2'-azobis(4-methoxy-2.4-dimethyl valeronitrile)；2,2'-azo-bis(2,4-dimethyl-4-methoxyvaleronitrile)；2,2'-azo-bis(4-methoxy-2,4-dimethylvaleronitrile)；2,2'-Azobis(4-methoxy-2,4-dimethylvaleronitrile)；2-[(2-cyano-4-methoxy-4-methylpentan-2-yl)diazenyl]-4-methoxy-2,4-dimethylpentanenitrile
• CAS: 15545-97-8
• 化学式: C₁₆H₂₈N₄O₂
• 分子量: 308.424
• InChiKey: PFHOSZAOXCYAGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  approximate 85℃approximate 85℃(decomposition)
• 沸点：
  389.8±42.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• LogP：
  2.3 at 25℃
• 物理描述：
  2,2'-azodi-(2,4-dimethyl-4-methoxyvaleronitrile) appears as a white to light-colored crystalline solid. Insoluble in water and denser than water. Contact may irritate skin, eyes and mucous membranes. May be toxic by ingestion. Used to make other chemicals.

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  90.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  偶氮二甲氧基异庚腈 以 氘代甲醇 为溶剂， 反应 20.0h， 生成
  参考文献：
  名称：

  JP2015/20967

  摘要：

  公开号：
• 作为产物：
  描述：

  4-甲氧基-4-甲基-2-戊酮 在 一水合肼 作用下， 生成 偶氮二甲氧基异庚腈
  参考文献：
  名称：

  Polyfurcate azonitriles

  摘要：

  公开号：

  US02586995A1
• 作为试剂：
  描述：

  1-丙烯基苯 、 2-溴丙二腈 在 偶氮二甲氧基异庚腈 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以68%的产率得到2-(2-bromo-1-methyl-2-phenylethyl)malononitrile
  参考文献：
  名称：

  Practical Radical Additions under Mild Conditions Using 2,2‘-Azobis(2,4-dimethyl-4-methoxyvaleronitrile) [V-70] as an Initiator

  摘要：

  Radical addition reactions of bromomalononitrile to various alkenes using 2,2'-azobis(2,4-dimethyl-4-methoxyvaleronitrile) (V-70) were examined. The advantages of V-70 which is an effective radical initiator at low temperature in contrast to the other azobis compounds are described, Especially V-70L (the low melting point diastereomer) was found to be the best radical initiator.

  DOI：

  10.1021/op970059z

文献信息

• Poly(vinyl ketone)s by Controlled Boron Group Transfer Polymerization (BGTP)
  作者：Kazuhiro Uehara、Christine B. Wagner、Thomas Vogler、Heinrich Luftmann、Armido Studer

  DOI：10.1002/anie.200907163

  日期：——

  Boron can do it! Readily prepared catecholboron enolates act as regulators in the controlled radical polymerization of alkyl and aryl vinyl ketones. Control is achieved by an unprecedented reversible radical boron group transfer (BGT) between enoyl radicals (see scheme). Polymers with Mn≤14 000 g mol−1 and a polydispersity index of 1.3 can be obtained by this process.

  硼可以做到！现成的儿茶酚硼烯酸酯在烷基和芳基乙烯基酮的受控自由基聚合中起调节剂的作用。通过烯醇基之间前所未有的可逆自由基硼基团转移（BGT）来实现控制（请参见方案）。与聚合物的中号Ñ ≤14000克摩尔-1和1.3的多分散性指数可以通过这种方法获得。
• Benzhydryl derivatives
  申请人：——

  公开号：US20030176430A1

  公开（公告）日：2003-09-18

  A compound of the formula (I): in which Z, R 1 , R 2 , R 8 , R 10 , R 11 , R 12 , R 13 and R 14 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism, and is useful for manufacture of a medicament for treating or preventing Tachykinin-mediated diseases.

  公式（I）的化合物：其中Z，R1，R2，R8，R10，R11，R12，R13和R14分别如说明书所定义，或其盐。本发明的目标化合物具有Tachykinin拮抗等药理活性，并可用于制造用于治疗或预防Tachykinin介导疾病的药物。
• Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US20020193614A1

  公开（公告）日：2002-12-19

  Novel anthranilic acid derivatives having an inhibiting activity of cGMP-PDE are represented by the formula I where A is a lower alkylene group: 1 The anthranilic acid derivatives show pharmacological activity and may be used in pharmaceutical compositions as medications. The anthranilic acid derivatives can be formed by the reaction of a fluoro precursor with an amine. Pharmaceutical compositions containing the anthranilic acid derivatives can be used to treat or prevent human health disorders.

  具有抑制cGMP-PDE活性的新型蒽酰胺衍生物通过公式I表示，其中A是较低的烷基烯基：1。这些蒽酰胺衍生物具有药理活性，并可用于制备药物组成物作为药物。这些蒽酰胺衍生物可以通过将氟前体与胺反应形成。含有这些蒽酰胺衍生物的药物组成物可用于治疗或预防人类健康疾病。
• Detergent compositions with copolymers of 1,2-dialkoxyethylenes and
  申请人：BASF Aktiengesellschaft

  公开号：US04980088A1

  公开（公告）日：1990-12-25

  Pulverulent and liquid detergents contain (1) one or more anionic surfactants, one or more nonionic surfactants or mixtures thereof and (2) copolymers in amounts of from 0.1 to 15% by weight preparable by copolymerization of (a) from 10 to 55 mol % of a 1,2-di-C.sub.1 -C.sub.4 -alkoxyethylene, (b) from 10 to 60 mol % of a monoethylenically unsaturated dicarboxylic anhydride of from 4 to 8 carbon atoms, (c) from 0 to 60 mol % of a monoethylenically unsaturated C.sub.3 -C.sub.8 -monocarboxylic acid and (d) from 0 to 20 mol % of another monoethylenically unsaturated monomer and subsequent hydrolysis of the anhydride groups of the copolymerized monomer (b) or reaction of these groups with an alcohol or an amine. Preferred copolymers contain 1,2 dimethoxyethylene as the (a) monomer, maleic acid as the (b) monomer, and acrylic acid as the (c) monomer.

  粉末和液体洗涤剂含有(1)一种或多种阴离子表面活性剂，一种或多种非离子表面活性剂或其混合物，以及(2)共聚物，其量为0.1至15重量％，可通过共聚反应制备(a)10至55摩尔％的1,2-二-C.sub.1-C.sub.4-烷氧基乙烯，(b)10至60摩尔％的4至8个碳原子的单乙烯不饱和二羧酸酐，(c)0至60摩尔％的单乙烯不饱和C.sub.3-C.sub.8-单羧酸和(d)0至20摩尔％的另一种单乙烯不饱和单体的共聚物，然后水解共聚单体(b)的酐基或将这些基团与醇或胺反应。首选的共聚物包含1,2-二甲氧基乙烯作为(a)单体，马来酸作为(b)单体和丙烯酸作为(c)单体。
• Process for producing acrylic acid derivative
  申请人：Nippon Soda Co. Ltd

  公开号：US20040152894A1

  公开（公告）日：2004-08-05

  Processes for producing a compound represented by the formula (1), which includes an acrylic acid derivative and is useful as an agricultural chemical or medicine. One of the processes comprises the step of formulating a compound (3) and converting the OH of the resultant compound (2) into OR″. The first step comprises reacting a formic or orthoformic ester in the presence of a Lewis acid and a base. The second step comprises reacting the compound with R″OH or with R″OH and CH(OR″) 3 under acidic conditions or using a phase-transfer catalyst in a two-phase system and regulating the base and the concentration thereof to stereoselectively synthesize the target compound. In another, process, the compound is efficiently produced without isolating the compound. The compound can also be produced without the compound (2). 1

  制备化合物（1）的工艺，该化合物包括丙烯酸衍生物，可用作农药或药物。其中一种工艺包括制备化合物（3），并将所得化合物（2）的OH转化为OR″。第一步包括在路易斯酸和碱的存在下反应甲酸酯或正甲酸酯。第二步包括在酸性条件下或使用相转移催化剂在两相体系中与R″OH或R″OH和CH（OR″）3反应，并调节碱和浓度以立体选择性地合成目标化合物。在另一种工艺中，化合物可以在不分离化合物（2）的情况下高效地生产。该化合物也可以在没有化合物（2）的情况下生产。

表征谱图